Ultragenyx to Participate in Investor Conferences in December

On November 24, 2025 Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, reported participation in two upcoming investor conferences.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Citi’s 2025 Global Healthcare Conference (Miami, FL)

Tuesday, December 2, 2025, Eric Crombez, M.D., Chief Medical Officer will participate in a fireside chat.
8th Annual Evercore ISI Healthcare Conference (Coral Gables, FL)

Wednesday, December 3, 2025, Eric Crombez will participate in a fireside chat.
The live and archived webcast of the fireside chats will be accessible from the company’s website at View Source

(Press release, Ultragenyx Pharmaceutical, NOV 24, 2025, View Source [SID1234660911])

Use the contact form at the top or bottom of this page to book a free demo to 1stOncology™, an all inclusive cancer drug development intelligence platform from BioSeeker. The platform provides value in oncology for you in areas such as:

Target scouting
Indication selection & expansion
Combinatorial drug settings
Drug repositioning
First in class analysis
Compound cross over analysis
Competitive analysis
Pathway analysis

and much more...

1stOncology is recognized as a
Top 10 Global Pharma Analytic Provider

Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers, signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology!